Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 12/20 | 0.58 |
| ▸ | GNAI3 | P08754 | 11/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9383358 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL9385204 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL7345197 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL9388856 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL5494333 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL9384220 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL9388213 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| SCHEMBL9389331 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| Hydrochloric Acid SCHEMBL7645440 | 0.98 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 | |
| Hydrochloric Acid SCHEMBL26090986 | 0.96 | GNAO1 (0.64) | GNAO1GNAI3GNAI1CYP1A2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104271114-B | Oral film containing opiate enteric release beads | LTS勒曼治疗系统股份公司 | 2019-12-03 | — | — | CN | claimed |
| US-9763879-B2 | Oral film containing opiate enteric-release beads | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2017-09-19 | — | — | US | claimed |
| US-9687445-B2 | Oral film containing opiate enteric-release beads | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2017-06-27 | — | — | US | claimed |
| US-9125833-B2 | Multimodal abuse resistant and extended release opioid formulations | RELMADA THERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | claimed |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION | 2015-05-07 | — | — | US | claimed |
| US-20150064231-A1 | Oral film containing opiate enteric-release beads | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2015-03-05 | — | — | US | claimed |
| EP-2836197-A1 | ORAL FILM CONTAINING OPIATE ENTERIC-RELEASE BEADS | LTS LOHMANN Therapie-Systeme AG (DE) | 2015-02-18 | — | — | EP | claimed |
| CN-104271114-A | Oral film containing opiate enteric release beads | LOHMANN THERAPIE SYST LTS | 2015-01-07 | — | — | CN | claimed |
| WO-2013171146-A1 | ORAL FILM CONTAINING ENTERIC RELEASE OPIATE RESINATE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2013-11-21 | — | — | WO | claimed |
| US-20130273162-A1 | Oral Film Containing Opiate Enteric-Release Beads | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2013-10-17 | — | — | US | claimed |
| EP-0986389-B1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040147754-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2004-07-29 | — | — | US | claimed |
| US-6716985-B2 | ALCOHOLISM, PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-06 | — | — | US | claimed |
| US-20020133011-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2002-09-19 | — | — | US | claimed |
| EP-0986389-A4 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2001-09-12 | — | — | EP | claimed |
| CN-1268889-A | Novel process for obtg. intermediates | SMITHKLINE BEECHAM CORP (US) | 2000-10-04 | — | — | CN | claimed |
| EP-0986389-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998053824-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-03 | — | — | WO | claimed |
| US-4146629-A | ANTIDEPRESSANTS | DELMAR CHEMICALS LIMITED (CA) | 1979-03-27 | — | — | US | claimed |
| US-4048314-A | ANTIDEPRESSANT | DELMAR CHEMICALS LIMITED (CA) | 1977-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133011-A1 | Novel process | HTR1A, HTR4, MAOA | GNAO1 2924/4885GNAI3 2908/4885GNAI1 2578/4885 |
| US-20150126554-A1 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | VIP, FABP2, SI | GNAO1 2416/4885GNAI3 1702/4885GNAI1 2606/4885 |
| US-20040147754-A1 | Novel process | HTR1A, HTR4, HTR2B | GNAO1 2757/4885GNAI3 2102/4885GNAI1 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.